ABMD News and Press, ABIOMED Inc. From 06/29/21

Abiomed’s (NASDAQ: ABMD) newest right heart pump, the Impella RP with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) as safe and effective to treat acute right heart failure for up to 14 days. This press release features multim...

SDI Productions/E+ via Getty Images A Data Safety Monitoring Board ("DSMB") has recommended that Abiomed's (ABMD) DanGer Shock trial of its Impella CP heart pump in patients with cardiogenic shock should continue, according to Piper Sandler.Citing a tweet from one of the lead investigators of...

Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affiliated Managers Group. The Glob...

Abiomed (ABMD) has acquired preCARDIA Minnesota-based developer of a proprietary catheter and controller targeting patients with acute decompensated heart failure ((ADHF)).preCARDIA system has received Breakthrough Device Designation from the FDA and the enrollment is complete in an...

My Roth IRA portfolio of 29 CEFs and 30 REITs for income, and 119 stocks for swing trading under-performing S&P 500 stocks, continues to realize profits. In May, I closed 8 stock trades for a net gain, including dividends, of 38.79% (median) or 34.65% (cost-weighted), for an avera...

Buy Dexcom, Abiomed, and Eargo on the dip: William BlairDexCom (DXCM), Abiomed (ABMD), and Eargo (EAR) have underperformed in the year so far, but citing their quarterly reports, William Blair’s Margaret Kaczor thinks the group of med-tech stocks are attractive buys on the pullback.Des...

Abiomed ([[ABMD]] -1.5%) is trading lower after Raymond James noted a potential impact on its biggest revenue generator Impella citing a new clinical trial posted by Boston Scientific ([[BSX]] -0.7%) on the federal clinical trial register.Impella is the only FDA-approved percutaneous heart pu...

Abiomed (NASDAQ: ABMD) reported its fiscal 2021 fourth-quarter earnings last week , with 17% year-over-year revenue growth of $243 million for the quarter. For many mature medical device companies, this would be a fantastic result. Unfortunately, for the full fiscal year, revenu...

Abiomed, Inc. (ABMD) Q4 2021 Earnings Conference Call April 29, 2021 8:00 AM ET Company Participants Todd Trapp – Vice President and Chief Financial Officer Mike Minogue – Chairman, President and Chief Executive Officer Conference Call Participants Margaret Kaczor – Willi...

Image source: The Motley Fool. Abiomed Inc (NASDAQ: ABMD) Q4 2021 Earnings Call Apr 29, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Abiomed Inc (ABMD) Q4 2021 Earnings Call Transcript